Powering the Age of Immune Medicine

JPM 2022 Healthcare Conference
Safe Harbor

This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and other future conditions. In some cases, you can identify forward-looking statements by the following words: "may," "will," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. All statements, other than statements of historical facts, contained in this presentation are forward looking statements, including statements regarding the ability to map adaptive immune responses to various disease states, including T cell responses to COVID-19 or other infectious diseases, as well as autoimmune disease and cancer, the ability to leverage any such findings to advance solutions to diagnose, treat and prevent infectious diseases or other diseases; regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective products and product candidates, including clonoSEQ, immunoSEQ T-MAP COVID and T-Detect products, planned non-IDE clinical studies, clinical trials and preclinical activities, research and development costs, current and prospective collaborations, including our collaborations in vaccine development; the estimated size of the market for our products and product candidates; the timing and success of our development and commercialization of our current and anticipated product candidates and the expansion of existing product lines such as T-Detect into additional indications; the availability and extent of reimbursement coverage by government and private payors; the availability of alternative therapies for our target markets; and the other risks and uncertainties described in our filings with the Securities and Exchange Commission including the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K, including our most recent Quarterly Report on Form 10-Q filed on November 3, 2021. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Risks and uncertainties could cause actual results to differ materially from those expressed in our forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.
T-cells taking center role in immunity to COVID-19

“Our findings underscore the fact that we need to look at **T cells**, not just antibodies, if we want a **complete picture** of the vaccine response for those who have **not had COVID-19** and for those who have **recovered from the disease**,” -E. John Wherry, PhD, Perelman School of Medicine at the University of Pennsylvania.
Key Catalysts 2022 -- Multiple levers to drive value

- **T-Detect COVID**: Enhance product profile (semi-quant data, correlate of protection)
- **T-Detect AI**: Increase sensitivity/specificity in MS, IBD, RA for market readiness
- **GNE collaboration**:
  - Advance lead shared candidate to development
  - Deliver 2 fully characterized additional shared candidates
  - Develop private product prototype
- **Nykode collaboration**: phase 1/2 data

- Obtain Medicare **coverage of DLBCL**
- Read-out data for use in **blood in MM/DLBCL**
- Expand adoption of MRD status as a co-/primary **clinical endpoint**
Using the immune system as the source-code for immune medicine
Business areas of focus

**Immune Medicine**

*Driven by immune receptor data opportunities*

- TAM ~$48B*

- T-Detect
  - Clinical Testing
  - Pharma Services

- Drug Discovery
  - Cell Therapy
  - Vaccines

**MRD**

*Driven by clonoSEQ/MRD assay applications*

- TAM ~$6B

- clonoSEQ
  - Clinical Testing
  - MRD Pharma

---

* Illustrative TAM for 3 indications for T-Detect (one infectious disease, one autoimmune disease, one oncology) and drug discovery in cell therapy oncology
Immune Medicine
Unique ability to map & identify disease specific TCR sequences

Immune Medicine Strategy
Create multiple value opportunities stemming from the same core disease data
T-Detect: one blood test that reads T cells to diagnose many diseases

One Blood Sample → Scale TCR-Antigen Map → T-Cell Based Diagnostic

TCRs

COVID-19
Lyme disease
Crohn’s disease
Multiple Sclerosis
Rheumatoid Arthritis
Ovarian cancer

Antigens
T-Detect most advanced indications

**COVID**

- Only FDA authorized test
- Medicare coverage for immunocompromised patients

**AUTOIMMUNE**

- Clinical signals in **five** diseases
- Crohn’s, colitis, celiac, MS, RA

**LYME**

- Study *Completed*
- Lyme season readiness
T-cells correlate with real world vaccine efficacy

Impact of Variants on Vaccine Response

Impact of Variants on Immune Response

Adaptive Biotechnologies, Seattle, Washington, USA; Stanford University School of Medicine, Stanford, California, USA
Increasing utility of T-Detect COVID

Current Offering

>30K users in 2021

Semi-Quantitative test

Monitor level of T-cell response

Correlate of Protection

Inform level of protection

Value Proposition

Time & Complexity (2022)
Developing T-Detect Autoimmune: a multi-disease blood test

Why Autoimmune Disorders?

T-Cells
- Highly disease specific
- Mechanistic linkage

T-Detect
- Molecular, blood-based test
- FDA authorized for COVID-19
- Same technology for all indications

Advancing multiple signals in parallel

All indications at high specificity

<table>
<thead>
<tr>
<th>Sensitivity</th>
<th>Signal</th>
<th>20-45%</th>
<th>45-70%</th>
<th>&gt;70%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ileal Crohn’s</td>
<td>confirmed</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colonic Crohn’s</td>
<td>identified</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colitis</td>
<td>identified</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celiac</td>
<td>confirmed</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MS</td>
<td>confirmed</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RA</td>
<td>identified</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Drug Discovery
Using the immune system to develop differentiated therapeutics

T-cell Therapeutics

T-cell based Vaccines

Antibodies

Drug Discovery

Novel targets and targeting molecules
Robust Drug Discovery pipeline

**Cell Therapy**
- **Exploratory** 1^st^ Shared
- **Discovery** 2^nd^ Shared
- **IND-Ready** Personalized
- **Clinical** TCR-Treg

**Vaccines**
- **COVID-19**

**Antibodies**
- **COVID-19**
- **Influenza A**
- **Cancer (pMHCs)**
- **Autoimmune (novel targets)**
MRD
Our MRD Heme business: synergistic value of pharma and clinical diagnostic

- **FDA cleared** in MM, ALL (BM*) and CLL (BM*, blood)
- **Broad coverage**: >240M lives
- **Widely adopted**: Clinical use in all 31 NCCN centers

**Clinical Testing**
- Pharma supports lifecycle expansion which drives clinical use
- Clinical usage drives inclusion as an endpoint in pharma trials

**MRD Trials**
- **Broad use** among major pharma in heme cancer trials
- Adopted by >40 biopharma companies
- >$330M in future regulatory milestones

* Bone marrow (BM)
MRD has evolved into an essential clinical decision-making tool.

Assess response to therapy

Escalate/de-escalate therapy

Detect relapse early

**MASTER trial**

Cumulative incidence of MRD resurgence or progression

96% of patients who stopped treatment after two clonoSEQ MRD negative tests did not progress.

Presented at ASH 2021: “Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial”
MRD business growth drivers

1. Expand Clinical Use
2. Extend indications & sample types
3. Commercial execution

*This use is not cleared or approved by the FDA and is available as part of Adaptive’s CLIA-validated LDT service*
Key Catalysts 2022 -- Multiple levers to drive value

- **Immune Medicine**
  - **T-Detect COVID**: Enhance product profile (semi-quant data, correlate of protection)
  - **T-Detect AI**: Increase sensitivity/specificity in MS, IBD, RA for market readiness
  - **GNE collaboration**:
    - Advance lead shared candidate to development
    - Deliver 2 fully characterized additional shared candidates
    - Develop private product prototype
  - **Nykode collaboration**: phase 1/2 data

- **MRD**
  - Obtain Medicare **coverage of DLBCL**
  - Read-out data for use in **blood in MM/DLBCL**
  - Expand adoption of MRD status as a co-/primary **clinical endpoint**
Thank You.